Cart
sales@molnova.com
Atuveciclib
CAS No. 1414943-88-6
Atuveciclib ( BAY 1143572;BAY1143572 )
Catalog No. M11720 CAS No. 1414943-88-6
Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 260 | Get Quote |
|
| 10MG | 416 | Get Quote |
|
| 25MG | 780 | Get Quote |
|
| 50MG | 1044 | Get Quote |
|
| 100MG | 1413 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAtuveciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.
-
DescriptionAtuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1; displays >150-fold selectivity over CDK1/2/3/5/6/7 (IC50>800 nM), also shows submicromolar inhibitory activity against GSK3α (IC50=45 nM), GSK3β (IC50=87nM); demonstrates antiproliferative activity against HeLa cells (IC50=920 nM) and MOLM‐13 cells (IC50=310 nM); exhibits anticancer activity in human AML models.Blood Cancer Phase 1 Clinical
-
SynonymsBAY 1143572;BAY1143572
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1414943-88-6
-
Formula Weight387.43
-
Molecular FormulaC18H18FN5O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(C)(CC1=CC=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=C1)=N
-
Chemical Name(3-((4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino)benzyl)(imino)(methyl)-l6-sulfanone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lücking U, et al. ChemMedChem. 2017 Nov 8;12(21):1776-1793.
2. Narita T, et al. Blood. 2017 Aug 31;130(9):1114-1124.
2. Narita T, et al. Blood. 2017 Aug 31;130(9):1114-1124.
molnova catalog
related products
-
SEL120-34A hydrochlo...
SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
Palbociclib
A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
